Result of AGM - 20 October 2017

Released : 20 Oct 2017 14:35

RNS Number : 2365U
Dechra Pharmaceuticals PLC
20 October 2017
 

 

 

Date: 20 October 2017

 

Dechra® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

 

 

AGM Meeting Date: 1pm on 20 October 2017

 

Issued Share Capital at meeting date: 93,415,750

 

Number of shareholders in attendance: 12

 

All resolutions were passed on a show of hands.

 

Details of the proxy voting instructions lodged prior to the AGM are set out below:

 

Resolution (No. as noted on proxy form)

 

Total For (1)

Total Against

Withheld (2)


No. of votes

% of vote

No. of votes

% of vote

No. of votes

Resolution 1:

To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report

 

69,787,352

94.83

3,801,367

5.17

176,986

Resolution 2:

To receive and approve the Directors' Remuneration Report

 

66,111,495

94.18

4,086,647

5.82

3,567,713

Resolution 3:

To receive and approve the Directors' Remuneration Policy

 

72,932,631

98.88

823,955

1.12

8,619

Resolution 4:

To declare a final dividend

 

73,764,546

100

0

0.00

659

Resolution 5:

To elect Richard Cotton

 

72,195,608

97.87

1,568,938

2.13

659

Resolution 6:

To elect Lawson Macartney

 

73,401,877

99.51

361,469

0.49

1,859

Resolution 7:

To re-elect Tony Rice

 

66,992,715

92.48

5,448,270

7.52

1,324,220

Resolution 8:

To re-elect Ian Page

 

72,285,663

98.00

1,478,883

2.00

659

Resolution 9:

To re-elect Anthony Griffin

 

72,279,341

97.99

1,485,205

2.01

659

Resolution 10:

To re-elect Julian Heslop

 

73,500,858

99.64

263,688

0.36

659

Resolution 11:

To re-elect Ishbel Macpherson

 

73,144,501

99.16

620,045

0.84

659

Resolution 12:

To reappoint PricewaterhouseCoopers as external auditor of the Company

 

73,756,778

99.99

7,318

0.01

1,109

Resolution 13:

To authorise the Audit Committee to determine the remuneration of the external auditor

 

73,763,069

100

1,027

0.00

1,109

Resolution 14:

To authorise the Directors to allot shares to specific limits

 

69,568,791

94.32

4,191,805

5.68

4,609

Resolution 15:

To disapply the pre-emption rights

 

72,858,327

98.78

903,219

1.22

3,659

Resolution 16:

To disapply additional pre-emption rights

 

67,395,228

91.37

6,366,318

8.63

3,659

Resolution 17:

To authorise the Company to purchase its own shares

 

72,978,224

99.07

685,466

0.93

101,515

Resolution 18:

To call general meetings (other than an AGM) on not less than 14 clear days' notice

 

71,828,591

97.38

1,935,505

2.62

1,109

Resolution 19:

(a)  To approve the rules of the LTIP 2017; and

(b)  To authorise the Directors to adopt further schemes based on the LTIP 2017

 

70,433,043

95.49

3,328,963

4.51

3,199

 

 

Notes

1.   Includes discretionary votes.

2.   A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

3.   Resolutions 1 to 14 and Resolution 19 were ordinary resolutions, requiring more than 50% of shareholder votes to be "for" the resolutions.

4.   Resolutions 15 to 18 were special resolutions, requiring more than 75% of shareholder votes to be "for" the resolutions.

5.   Votes tendered in respect of 73,765,205 shares representing 78.96% of the issued share capital.

 

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

 

 

For further information

 

Melanie Hall, Company Secretary                           

Telephone number: 01606 814730

 

 

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

 

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGFMMZGFGDGNZM